Prils Market Size & Share, by Type (Amipril, Quinapril, Cilazapril, Benazepril); Distribution Channel (Hospital, Pharmacies); Application (Hypertension, Heart Failure, Chronic Kidney Disorder) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 4109
  • Published Date: Aug 08, 2023
  • Report Format: PDF, PPT

Companies Dominating the Prils Market

top-features-companies
    • Teva Pharmaceuticals Industries Ltd.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Boehringer Ingelheim International GmbH
    • Sun Pharmaceuticals Industries Ltd.
    • Pfizer Inc.
    • Mylan N.V
    • F. Hoffmann-La Roche Ltd.
    • Novartis AG
    • Manus Aktteva Biopharma LLP
    • Canagen Pharmaceuticals Inc.
    • Lupin Limited

Browse Key Market Insights with Data Illustration:

In-the-news

In The News

  • Lupin Limited entered into a contract with Medis for Lupin’s orphan drug NaMuscla (mexiletine). Further, for the symptomatic management of people with non-dystrophic myotonic (NDM) diseases, Medis will market NaMuscla in Central and Eastern European nations.
  • Novartis AG collaborated with Dr. Reddy's Laboratories which is exclusive for certain of its well-known medications, such as the Voveran range, the Calcium range, and Methergine. Further, the agreement aims to increase patient’s access to these medications beyond present geographic boundaries.

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 4109
  • Published Date: Aug 08, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Rising geriatric population and the growing incidences of cardiovascular diseases are the major factors driving the market growth

The market size of prils is anticipated to attain a CAGR of 6% over the forecast period, i.e., 2023 – 2035.

The market in the North America region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are Novartis AG, Manus Aktteva Biopharma LLP, Canagen Pharmaceuticals Inc., and Lupin Limited., and others.

The hypertension segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying